Max Chat
Calendrier des promotions Delcath Systems, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.Paramètres de base
IPO date
2018-05-29
ISIN
US24661P8077
Industry
Health Care Equipment & Supplies
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 9.11 | 1 |
| P/BV | 4.93 | 3 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -45.81 | 0 |
| ROE | -62.44 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0836 | 10 |
| Debt/Ratio | 0.0136 | 10 |
| Debt/Equity | 0.1141 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 2225.31 | 10 |
| Rentabilité Ebitda, % | -40.9 | 0 |
| Rentabilité EPS, % | -89.05 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 15.34 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 15.96 $ | 0 $ | 0 $ | -3.88 % | 0 % | 0 % |
| common.calendar.number_days.30d | 16.11 $ | 15.34 $ | 16.87 $ | -4.78 % | 0 % | 0 % |
| common.calendar.number_days.90d | 10.66 $ | 10.39 $ | 18.1 $ | 43.9 % | 0 % | 0 % |
| common.calendar.number_days.180d | 16.25 $ | 10.39 $ | 18.1 $ | -5.6 % | 0 % | 0 % |
| common.calendar.number_days.1y | 10.64 $ | 7.36 $ | 18.1 $ | 44.17 % | 0 % | 0 % |
| common.calendar.number_days.3y | 4.18 $ | 2.25 $ | 18.1 $ | 266.99 % | 0 % | 0 % |
| common.calendar.number_days.5y | 12.6 $ | 2.25 $ | 23.81 $ | 21.75 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.005 $ | 0.005 $ | 28.77 $ | 306800.01 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 16.25 $ | 10.39 $ | 18.1 $ | -5.6 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Gerard J. Michel MBA, MS | CEO & Director | 727.97k | 1963 (62 année) |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations & Medical Affairs | 472.16k | 1965 (60 années) |
| Ms. Sandra Pennell | Senior VP of Finance and Principal Financial & Accounting Officer | N/A | 1980 (45 années) |
| Mr. David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | N/A | |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer | N/A | 1970 (55 années) |
| Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer | 1967 (58 années) |
Informations sur l'entreprise
Adresse: United States, New York. NY, 1633 Broadway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.delcath.com
Site web: https://www.delcath.com
